title: Persistence with antihypertensive treatments: results of a 3-year follow-up cohort study.
abstract: OBJECTIVE
  Effective treatment of hypertension requires continued prescribing of antihypertensive medications for many years. Persistence in prescribing habits, however, has been reported to be low. The study described herein - which is completely independent of pharmaceutical sponsors - was undertaken to evaluate persistence with antihypertensive treatment in Germany.
  
  
  METHODS
  A total of 13,763 newly diagnosed hypertensive patients were identified in the IMS Disease Analyzer database and observed for 3 years after their first antihypertensive prescription.
  
  
  RESULTS
  The median age of the study cohort was 65 years, and 56% were female. One in four patient received no more than three prescriptions within 3 years. Persistence was longest for patients whose initial prescription was for a free combination based on angiotensin converting enzyme inhibitors (median: 392.5 days), followed patients initially receiving a fixed combination, including angiotensin II receptor antagonists (208.5 days) and AIIRA monotherapy (168 days). Persistence was shortest with diuretics (57 days). Across all treatment groups, persistence after 3 years was 15.2%. Insurance status, sex and comorbidities were not found to impact persistence.
  
  
  CONCLUSIONS
  Our data indicate that persistence differs markedly among the drug classes (p < or = 0.001) but that even persistence of the best drug class is not sufficient to provide for an adequate blood pressure control in the population. The largest decline in persistence occurred in the first 3 months of treatment. More research is needed to elucidate the causes of this early drop in persistence and to develop effective means of improving the currently unsatisfactory situation.
authors: IBE - Department of Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-Universität München, Marchioninistr. 15, 81377, Munich, Germany. has@ibe.med.uni-muenchen.de
authors: Joerg
authors: J
authors: Hasford
authors: Detlef
authors: D
authors: Schröder-Bernhardi
authors: Marietta
authors: M
authors: Rottenkolber
authors: Karel
authors: K
authors: Kostev
authors: Gerhard
authors: G
authors: Dietlein
mesh_terms: D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D015331:Cohort Studies; D015897:Comorbidity; D016208:Databases, Factual; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005858:Germany; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D019458:Insurance Coverage; D008297:Male; D008875:Middle Aged; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D012737:Sex Factors; D013997:Time Factors
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D004338:Drug Combinations
references: JAMA. 2003 May 14;289(18):2363-9
references: 12746359
references: Am J Manag Care. 2005 Nov;11(13 Suppl):S395-9
references: 16300455
references: Ann Pharmacother. 1995 Dec;29(12):1213-17
references: 8672823
references: BMC Med. 2005 Jan 05;3:2
references: 15629061
references: Manag Care. 2003 Aug;12(8 Suppl Hypertension):56-61
references: 12971594
references: J Clin Hypertens (Greenwich). 2003 Mar-Apr;5(2):127-32
references: 12671325
references: Int J Clin Pharmacol Ther. 2002 Mar;40(3):130-3
references: 11911603
references: J Hypertens. 2005 Nov;23(11):2093-100
references: 16208153
references: Cochrane Database Syst Rev. 2004;(2):CD004804
references: 15106262
references: J Hypertens. 2004 Oct;22(10):1849-55
references: 15361751
references: CMAJ. 1999 Jan 12;160(1):41-6
references: 9934342
references: Arch Intern Med. 1997 Nov 24;157(21):2413-46
references: 9385294
references: JAMA. 2002 Dec 18;288(23):2981-97
references: 12479763
references: N Engl J Med. 2005 Aug 4;353(5):487-97
references: 16079372
references: Ann Pharmacother. 2005 Sep;39(9):1401-8
references: 16076920
references: Curr Opin Cardiol. 2005 Jul;20(4):296-300
references: 15956826
references: Eur J Clin Pharmacol. 2004 Apr;60(2):135-42
references: 15042351
references: Eur J Clin Pharmacol. 2005 Sep;61(8):603-9
references: 16082539
references: Can J Clin Pharmacol. 2004 Fall;11(2):e267-73
references: 15596883
references: Pharmacoepidemiol Drug Saf. 2005 Nov;14(11):795-803
references: 16178043
references: J Clin Epidemiol. 2006 Jan;59(1):11-7
references: 16360556
references: Manag Care. 2001 Feb;10(2):42-5
references: 11236643
references: Herz. 2004 May;29(3):271-5
references: 15167953
references: J Hum Hypertens. 2002 Aug;16(8):569-75
references: 12149663
references: Manag Care. 2000 Sep;9(9 Suppl):2-6
references: 11729417
references: BMJ. 1995 Jul 29;311(7000):293-5
references: 7633238